VALDISERRA, GIULIA Statistiche
VALDISERRA, GIULIA
DIPARTIMENTO DI RICERCA TRASLAZIONALE E DELLE NUOVE TECNOLOGIE IN MEDICINA E CHIRURGIA
Communicating Drug Safety
2024-01-01 Tuccori, Marco; Convertino, Irma; Ferraro, Sara; Bonaso, Marco; Valdiserra, Giulia; Cappello, Emiliano
Evaluation of the beneficial effects of a GABA-based product containing Melissa officinalis on post-inflammatory irritable bowel syndrome: a preclinical study
2024-01-01 Lucarini, E.; Benvenuti, L.; Di Salvo, C.; D'Antongiovanni, V.; Pellegrini, C.; Valdiserra, G.; Ciampi, C.; Antonioli, L.; Lambiase, C.; Cancelli, L.; Grosso, A.; Di Cesare Mannelli, L.; Bellini, M.; Ghelardini, C.; Fornai, M.
Lessons learnt from the preclinical discovery and development of ensitrelvir as a COVID-19 therapeutic option
2024-01-01 Ferraro, Sara; Convertino, Irma; Cappello, Emiliano; Valdiserra, Giulia; Bonaso, Marco; Tuccori, Marco
The pharmacological blockade of P2X4 receptor as a viable approach to manage visceral pain in a rat model of colitis
2024-01-01 Di Salvo, C.; D'Antongiovanni, V.; Benvenuti, L.; Fornai, M.; Valdiserra, G.; Natale, G.; Ryskalin, L.; Lucarini, E.; Mannelli, L. D. C.; Ghelardini, C.; Colucci, R.; Hasko, G.; Pellegrini, C.; Antonioli, L.
Analysis of the Drug Related Emergency Department Admissions in Tuscany: The FARO Project
2023-01-01 Valdiserra, G; Cappello, E; Bonaso, M; Ferraro, S; Convertino, I; Crescioli, G; Lombardi, N; Tuccori, M
Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy
2023-01-01 Convertino, I.; Cazzato, M.; Tillati, S.; Giometto, S.; Gini, R.; Valdiserra, G.; Cappello, E.; Ferraro, S.; Bonaso, M.; Bartolini, C.; Paoletti, O.; Lorenzoni, V.; Trieste, L.; Filippi, M.; Turchetti, G.; Cristofano, M.; Blandizzi, C.; Mosca, M.; Lucenteforte, E.; Tuccori, M.
Discontinuation rate to biologic and targeted synthetic DMARDs in rheumatoid arthritis patients: Systematic review and meta-analysis
2023-01-01 Convertino, I; Lucenteforte, E; Arzenton, E; Giometto, S; De Luca, G; Malanima, M; Ferraro, S; Bonaso, M; Cappello, E; Valdiserra, G; Cazzato, M; Moretti, U; Mosca, M; Gini, R; Tuccori, M
Disproportionality Analysis of ‘‘Early-Onset’’ Tardive Dyskinesia Stratified by Time to Onset Using FAERS Database.
2023-01-01 Cappello, E; Valdiserra, G; Bonaso, M; Ferraro, S; Convertino, I; Flaccavento, A; Tuccori, M
Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis
2023-01-01 Convertino, I.; Lorenzoni, V.; Gini, R.; Turchetti, G.; Fini, E.; Giometto, S.; Bartolini, C.; Paoletti, O.; Ferraro, S.; Cappello, E.; Valdiserra, G.; Bonaso, M.; Blandizzi, C.; Tuccori, M.; Lucenteforte, E.
Erratum to: Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System (Drug Safety, (2023), 46, 3, (283-295), 10.1007/s40264-022-01269-x)
2023-01-01 Cappello, E.; Valdiserra, G.; Bonaso, M.; Ferraro, S.; Convertino, I.; Tuccori, M.
Fatal Fat Overload Syndrome Following Intravenous Lipid Emulsion Administration as Antidote in Suspected Anesthetic Intoxication: A Fatal Medication Error.
2023-01-01 Bonaso, M; Cappello, E; Convertino, I; Ferraro, S; Valdiserra, G; Tuccori, M
Raynaud’s Phenomenon Associated with Calcitonin Gene-Related Peptide (CGRP) Antagonists: a Disproportionality Analysis on VigiBase
2023-01-01 Valdiserra, G; Cappello, E; Ferraro, S; Convertino, I; Bonaso, M; Moretti, U; Tuccori, M
Supporting the Spontaneous Reporting by Health Care Professionals of the University Hospital of Pisa, Italy: a Pilot Project from the Unit of Adverse Drug Reactions Monitoring
2023-01-01 Cappello, E; Valdiserra, G; Bonaso, M; Convertino, I; Ferraro, S; Tuccori, M
Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence
2023-01-01 Convertino, Irma; Ferraro, Sara; Cappello, Emiliano; Valdiserra, Giulia; Bonaso, Marco; Tuccori, Marco
COVID-19 Vaccines and Thromboembolic Events with Thrombocytopenia: Data from Italian Pharmacovigilance Public Database
2022-01-01 Bonaso, M.; Marchione, P.; Felicetti, P.; Petronzelli, F.; Cappello, E.; Samez, S.; Zappetti, C.; Rossi, P.; Merlano, C.; Valdiserra, G.; Ferraro, S.; Convertino, I.; Marra, A. R.; Parrilli, M.; Tuccori, M.
Evaluation of drug-utilization and healthcare facilities use in patients with ulcerative colitis and treated with biologic therapy using data of an Italian healthcare administrative database: Results from michelangelo study
2022-01-01 Ferraro, Sara; Paoletti, Olga; Giometto, Sabrina; Tillati, Silvia; Convertino, Irma; Valdiserra, Giulia; Cappello, Emiliano; Bonaso, Marco; Bartolini, Claudia C.; Lorenzoni, Valentina; Turchetti, Giuseppe; Gini, Rosa; Fornai, Matteo; Lucenteforte, Ersilia; Tuccori, Marco
Exploring the relationship between utilization patterns of biologic disease-modifying anti-rheumatic drugs and disease activity in rheumatoid arthritis patients
2022-01-01 Convertino, Irma; Cazzato, Massimiliano; Tillati, Silvia; Giometto, Sabrina; Gini, Rosa; Valdiserra, Giulia; Cappello, Emiliano; Ferraro, Sara; Bonaso, Marco; Bartolini, Claudia C.; Paoletti, Olga; Lorenzoni, Valentina; Filippi, Matteo; Turchetti, Giuseppe; Cristofano, Michele; Blandizzi, Corrado; Mosca, Marta; Lucenteforte, Ersilia; Tuccori, Marco
Oral Presentation: Signal of Hypertension Associated with COVID-19 Vaccination: VigiBase (R) Data and Evidence from Real World
2022-01-01 Bonaso, M.; Moretti, U.; Valdiserra, G.; Cappello, E.; Convertino, I.; Ferraro, S.; Tuccori, M.
Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall
2022-01-01 Tuccori, Marco; Convertino, Irma; Ferraro, Sara; Cappello, Emiliano; Valdiserra, Giulia; de Luca, Giulia; Franchini, Massimo; Focosi, Daniele
An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future
2021-01-01 Tuccori, M.; Convertino, I.; Ferraro, S.; Valdiserra, G.; Cappello, E.; Fini, E.; Focosi, D.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Communicating Drug Safety | 1-gen-2024 | Tuccori, Marco; Convertino, Irma; Ferraro, Sara; Bonaso, Marco; Valdiserra, Giulia; Cappello, Emiliano | |
| Evaluation of the beneficial effects of a GABA-based product containing Melissa officinalis on post-inflammatory irritable bowel syndrome: a preclinical study | 1-gen-2024 | Lucarini, E.; Benvenuti, L.; Di Salvo, C.; D'Antongiovanni, V.; Pellegrini, C.; Valdiserra, G.; Ciampi, C.; Antonioli, L.; Lambiase, C.; Cancelli, L.; Grosso, A.; Di Cesare Mannelli, L.; Bellini, M.; Ghelardini, C.; Fornai, M. | |
| Lessons learnt from the preclinical discovery and development of ensitrelvir as a COVID-19 therapeutic option | 1-gen-2024 | Ferraro, Sara; Convertino, Irma; Cappello, Emiliano; Valdiserra, Giulia; Bonaso, Marco; Tuccori, Marco | |
| The pharmacological blockade of P2X4 receptor as a viable approach to manage visceral pain in a rat model of colitis | 1-gen-2024 | Di Salvo, C.; D'Antongiovanni, V.; Benvenuti, L.; Fornai, M.; Valdiserra, G.; Natale, G.; Ryskalin, L.; Lucarini, E.; Mannelli, L. D. C.; Ghelardini, C.; Colucci, R.; Hasko, G.; Pellegrini, C.; Antonioli, L. | |
| Analysis of the Drug Related Emergency Department Admissions in Tuscany: The FARO Project | 1-gen-2023 | Valdiserra, G; Cappello, E; Bonaso, M; Ferraro, S; Convertino, I; Crescioli, G; Lombardi, N; Tuccori, M | |
| Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy | 1-gen-2023 | Convertino, I.; Cazzato, M.; Tillati, S.; Giometto, S.; Gini, R.; Valdiserra, G.; Cappello, E.; Ferraro, S.; Bonaso, M.; Bartolini, C.; Paoletti, O.; Lorenzoni, V.; Trieste, L.; Filippi, M.; Turchetti, G.; Cristofano, M.; Blandizzi, C.; Mosca, M.; Lucenteforte, E.; Tuccori, M. | |
| Discontinuation rate to biologic and targeted synthetic DMARDs in rheumatoid arthritis patients: Systematic review and meta-analysis | 1-gen-2023 | Convertino, I; Lucenteforte, E; Arzenton, E; Giometto, S; De Luca, G; Malanima, M; Ferraro, S; Bonaso, M; Cappello, E; Valdiserra, G; Cazzato, M; Moretti, U; Mosca, M; Gini, R; Tuccori, M | |
| Disproportionality Analysis of ‘‘Early-Onset’’ Tardive Dyskinesia Stratified by Time to Onset Using FAERS Database. | 1-gen-2023 | Cappello, E; Valdiserra, G; Bonaso, M; Ferraro, S; Convertino, I; Flaccavento, A; Tuccori, M | |
| Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis | 1-gen-2023 | Convertino, I.; Lorenzoni, V.; Gini, R.; Turchetti, G.; Fini, E.; Giometto, S.; Bartolini, C.; Paoletti, O.; Ferraro, S.; Cappello, E.; Valdiserra, G.; Bonaso, M.; Blandizzi, C.; Tuccori, M.; Lucenteforte, E. | |
| Erratum to: Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System (Drug Safety, (2023), 46, 3, (283-295), 10.1007/s40264-022-01269-x) | 1-gen-2023 | Cappello, E.; Valdiserra, G.; Bonaso, M.; Ferraro, S.; Convertino, I.; Tuccori, M. | |
| Fatal Fat Overload Syndrome Following Intravenous Lipid Emulsion Administration as Antidote in Suspected Anesthetic Intoxication: A Fatal Medication Error. | 1-gen-2023 | Bonaso, M; Cappello, E; Convertino, I; Ferraro, S; Valdiserra, G; Tuccori, M | |
| Raynaud’s Phenomenon Associated with Calcitonin Gene-Related Peptide (CGRP) Antagonists: a Disproportionality Analysis on VigiBase | 1-gen-2023 | Valdiserra, G; Cappello, E; Ferraro, S; Convertino, I; Bonaso, M; Moretti, U; Tuccori, M | |
| Supporting the Spontaneous Reporting by Health Care Professionals of the University Hospital of Pisa, Italy: a Pilot Project from the Unit of Adverse Drug Reactions Monitoring | 1-gen-2023 | Cappello, E; Valdiserra, G; Bonaso, M; Convertino, I; Ferraro, S; Tuccori, M | |
| Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence | 1-gen-2023 | Convertino, Irma; Ferraro, Sara; Cappello, Emiliano; Valdiserra, Giulia; Bonaso, Marco; Tuccori, Marco | |
| COVID-19 Vaccines and Thromboembolic Events with Thrombocytopenia: Data from Italian Pharmacovigilance Public Database | 1-gen-2022 | Bonaso, M.; Marchione, P.; Felicetti, P.; Petronzelli, F.; Cappello, E.; Samez, S.; Zappetti, C.; Rossi, P.; Merlano, C.; Valdiserra, G.; Ferraro, S.; Convertino, I.; Marra, A. R.; Parrilli, M.; Tuccori, M. | |
| Evaluation of drug-utilization and healthcare facilities use in patients with ulcerative colitis and treated with biologic therapy using data of an Italian healthcare administrative database: Results from michelangelo study | 1-gen-2022 | Ferraro, Sara; Paoletti, Olga; Giometto, Sabrina; Tillati, Silvia; Convertino, Irma; Valdiserra, Giulia; Cappello, Emiliano; Bonaso, Marco; Bartolini, Claudia C.; Lorenzoni, Valentina; Turchetti, Giuseppe; Gini, Rosa; Fornai, Matteo; Lucenteforte, Ersilia; Tuccori, Marco | |
| Exploring the relationship between utilization patterns of biologic disease-modifying anti-rheumatic drugs and disease activity in rheumatoid arthritis patients | 1-gen-2022 | Convertino, Irma; Cazzato, Massimiliano; Tillati, Silvia; Giometto, Sabrina; Gini, Rosa; Valdiserra, Giulia; Cappello, Emiliano; Ferraro, Sara; Bonaso, Marco; Bartolini, Claudia C.; Paoletti, Olga; Lorenzoni, Valentina; Filippi, Matteo; Turchetti, Giuseppe; Cristofano, Michele; Blandizzi, Corrado; Mosca, Marta; Lucenteforte, Ersilia; Tuccori, Marco | |
| Oral Presentation: Signal of Hypertension Associated with COVID-19 Vaccination: VigiBase (R) Data and Evidence from Real World | 1-gen-2022 | Bonaso, M.; Moretti, U.; Valdiserra, G.; Cappello, E.; Convertino, I.; Ferraro, S.; Tuccori, M. | |
| Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall | 1-gen-2022 | Tuccori, Marco; Convertino, Irma; Ferraro, Sara; Cappello, Emiliano; Valdiserra, Giulia; de Luca, Giulia; Franchini, Massimo; Focosi, Daniele | |
| An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future | 1-gen-2021 | Tuccori, M.; Convertino, I.; Ferraro, S.; Valdiserra, G.; Cappello, E.; Fini, E.; Focosi, D. |